Provenge Survival Data Plagued by Small Study Size, Post hoc Analysis
Executive Summary
The Cellular, Tissue and Gene Therapies Advisory Committee's favorable recommendation on the efficacy of Dendreon's Provenge could give FDA greater confidence in accepting the post hoc survival analysis and approving the cancer vaccine